Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature

Yun Lin^{1,*}Qun Li^{1,*}Wei Huang¹Xinyan Jia¹Hong Jiang¹Yong Gao¹Qi Li^{1,2}

¹Department of Oncology, Shanghai East Hospital, ²Department of Oncology, Shanghai First People's Hospital, Shanghai, People's Republic of China

*These authors contributed equally to this work, and are joint first authors

Introduction: To date, no effective systemic therapies have been made available for paraganglioma. However, multiple mutations in susceptibility genes have been identified that are potential targets for sorafenib, an oral multitargeted tyrosine-kinase inhibitor.

Case presentation: We report the case of a 69-year-old Chinese man with mediastinal paraganglioma that had metastasized to the bone. The paraganglioma responded to sorafenib, a novel multi-tyrosine kinase inhibitor that targets angiogenesis, the Raf-kinase pathway, the platelet-derived growth factor Ret, and c-Kit. The patient was diagnosed as having paraganglioma after biopsy of the mediastinal mass. We first treated the patient with radiotherapy. Then he tolerated an etoposide-and-cisplatin chemotherapy regimen. Subsequently, he received 6 months of maintenance treatment with sorafenib (400 mg twice daily). A dramatic reduction in tumor volume was observed. At present, the patient has achieved a partial response, and his clinical status remains unchanged.

Conclusion: We suggest that sorafenib should be further investigated in the management of patients with paraganglioma.

Keywords: sorafenib, paraganglioma, molecular-targeted drug

Introduction

Paragangliomas are rare neuroendocrine tumors, occurring in two to eight persons per million, with a maximum incidence in the third or fourth decade of life.¹ They can arise anywhere from the upper neck to the pelvic floor along the paraganglion system. Paragangliomas are frequently hereditary and/or multifocal. Paragangliomas could be benign or malignant; there is no histologic criterion to differentiate between the two. Only metastases, occurring in approximately 10% of patients, present evidence of malignancy. Paragangliomas can metastasize to bone, the lungs, and lymph nodes.² No more than 30 cases of mediastinal paraganglioma have been reported in the literature.

To date, no effective systemic therapy has existed for patients with paraganglioma. Surgical excision is the main treatment of choice. Tyrosine-kinase inhibitors (TKIs), such as sunitinib, already approved for kidney cancer, proved to be a treatment option for refractory paragangliomas.³ In 2012, Gunaldi et al reported a case of a woman with metastatic paragangliomas who showed complete response to another TKI – sorafenib.⁴ Sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals, Montville, NJ, USA) is an oral multitargeted TKI that mainly targets the receptor tyrosine kinases, vascular endothelial growth factor receptors (VEGFRs) 1–3, platelet-derived growth-factor (PDGF) receptor, and Raf kinases, as well as the non-receptor serine threonine kinases B-Raf proto-oncogene serine/threonine-protein kinase and C-Raf

Correspondence: Qi Li/Yong Gao
Department of Oncology,
Shanghai First People's Hospital,
Shanghai Jiaotong University,
100 Haining Road, Shanghai 200080/
Department of Oncology, Shanghai East
Hospital, Tongji University School of
Medicine, 150 Jimo Road, Shanghai 200120,
People's Republic of China
Tel +86 138 1820 7333/21 6156 9716
Email leeqi2001@hotmail.com/gaoyon@
hotmail.com

proto-oncogene serine/threonine-protein kinase.^{5,6} Sorafenib has been shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC).^{7,8}

Case presentation

In this report, we discuss a case of paraganglioma that arose in the anterior mediastinal compartment. In December 2009, a 69-year-old patient was referred to our unit, complaining of chest pain and tightness. He had an Eastern Cooperative Oncology Group performance status of 2. A computed tomography (CT) scan showed an anterior mediastinal mass (87.1×75.0 mm, Figure 1A), accompanied by multiple mediastinal lymph-node metastases, hydropericardium, and lumbar vertebrae metastases. Histologic examination revealed a solid cellular proliferation with an alveolar and focally diffuse architecture. The examination further revealed groups of cells with characteristic *Zellballen* nested appearance (Figure 2). Immunohistochemical staining was positive for Ki-67, CD56, chromogranin A, and synaptophysin. On the basis of the histologic and immunohistochemical features, a diagnosis of paraganglioma was proposed (Figure 3). The cell groups were composed of polyhedral cells with granular amphophilic cytoplasm. Plasma cortisol and adrenocorticotropic hormone levels were normal. Because multiorgan metastases were present, surgery was not indicated.

In general, chemotherapy and radiotherapy have not demonstrated convincing results for patients with unresectable or metastatic disease. We first treated our patient with radiotherapy. The clinical target volume (CTV) included the mass and mediastinal lymph nodes (LNs). The planning target

Figure 2 Hematoxylin and eosin staining of the biopsied specimen. Groups of cells have a characteristic *Zellballen* nested appearance. The groups of cells were composed of polyhedral cells with granular amphophilic cytoplasm.

volume (PTV) included the CTV with margins extended by 0.5–1.0 cm. The prescribed dose for the PTV was 50.0 Gy in 28 fractions with 6 MV X-ray. A month later, a chest CT scan showed that the size of the mass had shrunk to 60.5×47.6 mm (Figure 1B). Our patient then received palliative chemotherapy with etoposide and cisplatin (EP) for four cycles. The EP regimen comprised of etoposide (100 mg/m^2 intravenously) and cisplatin (75 mg/m^2 intravenously) on day 1 every 3 weeks. Two months after chemotherapy, a CT scan indicated stable disease, with a mass size of 54.6×40.4 mm (Figure 1C).

After extensive discussions with the patient's family about the risks and benefits of therapy, the patient began off-label use of sorafenib. Sorafenib was initiated at a starting dose of 400 mg twice daily. After 60 days, there was a

Figure 1 (A) Baseline computed tomography (CT) scan of the chest with contrast on initial evaluation. (B) Follow-up CT scan at 1 month after radiotherapy. (C) A CT scan taken 2 months after chemotherapy indicating stable disease. (D) A CT scan taken 60 days later showing dramatic improvement in the mediastinal tumor after treatment with oral sorafenib 400 mg twice per day.

Figure 3 (A–D) Immunohistochemical staining of the biopsied specimen. Immunohistochemical staining was positive for Ki-67 (A), CD56 (B), chromogranin A (C), and synaptophysin (D), demonstrating sustentacular cells around the periphery of the cell nests and supporting the diagnosis of paraganglioma (immunohistochemistry, EnVision).

dramatic improvement in the mediastinal tumor: the mass size decreased to 43.5×27.1 mm (Figure 1D). Our patient was followed up monthly. He remained well, with stable disease. Overall, tolerance of sorafenib therapy was good. A mild rash developed on the patient's back. Sorafenib also resulted in marked fatigue as an initial side effect. Because the dramatic positive clinical response that we observed was accompanied by significant fatigue within 6 months of treatment, we decreased the sorafenib dose to a maintenance dose of 200 mg daily. As per the Response Evaluation Criteria in Solid Tumors evaluation criteria, a partial response was described in accordance with a 30% or greater decrease in the sum of diameters of target lesions.⁹

Written informed consent was obtained from the patient for publication of this case report and all accompanying images. A copy of the written consent is available for review by the editor-in-chief of this journal.

Discussion

Paragangliomas are tumors derived from the adrenal medulla or extra-adrenal ganglia. They are rare and often benign tumors that are associated with high morbidity and mortality due to mass effect and high circulating catecholamines. Although most paragangliomas are thought to be sporadic, over one-third are associated with susceptibility genes. A germ-line mutation in a paraganglioma susceptibility gene was identified in the *SDHx* genes,^{10,11} *VHL*,^{12,13} *RET*,¹⁴ and *TMEM127*.^{15–17} Recently, the Myc-associated factor X gene¹⁴ and *VEGFR2* have also been identified as related to paragangliomas.^{16–18} To diagnose paraganglioma, histologic and immunohistochemical evaluations are necessary.

The ideal treatment for metastatic paragangliomas remains elusive. Targeted therapy has not been evaluated sufficiently in patients with paragangliomas. Sorafenib, an oral multitargeted TKI, is currently approved by the US Food and Drug Administration for the treatment of advanced and unresectable HCC and RCC. Sorafenib has activity against Raf kinase, VEGFR2, PDGF, Flt-3, Ret, and c-Kit.¹⁹ A review of the literature shows treatment of such TKIs as sunitinib showed partial response for refractory paragangliomas,³ and a case of a woman with metastatic paragangliomas showed complete response to sorafenib.⁴ In the sorafenib case, the mass was first excised; after local recurrence and metastases, she received chemotherapy and subsequent targeted therapy with sorafenib. Our patient had metastasis to the bone in primary diagnosis and could not be excised, but after radiotherapy and chemotherapy, and subsequent targeted therapy with sorafenib, we also attained a truly stable disease – a major

clinical benefit. This confirmed previous reports of successful use of targeted therapy in paraganglioma. Skin rash is a common adverse reaction to sorafenib, occurring within weeks of the start of treatment. However, our patient only developed a mild rash. It has been suggested that sorafenib may be efficacious for paragangliomas because it targets several different cellular pathways. Because these tumors are extremely variable in terms of the molecules they express, a broader approach to these targets seems reasonable.

The surprising success of sorafenib treatment also raises some questions and could be a matter of debate. For instance, one could assume that mutations or alterations to the genomic profile of our patient's tumor made it especially sensitive to sorafenib. The surprising outcome of our patient also demonstrates that more research is needed to understand the molecular mechanisms involved in paragangliomas and to find potential targets for future therapy development.

Acknowledgments

This study was supported by grants from the Natural Science Foundation of China (81071664 and 81272714 to Qi Li) and the Shanghai Pujiang Programme (13PJJD025 to Qi Li, PKJ2010-Y09 to Yun Lin, and PWRq2011-16 to Qun Li).

Disclosure

The authors report no conflicts of interest in this work.

References

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs*. Lyon: IARC; 2004.
2. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. *J Natl Cancer Inst*. 2003;95:1196–1204.
3. Dettino AA, Guimaraes GC, Formiga M, et al. Pheochromocytoma (PC)/paraganglioma (PG) and sunitinib: Review of reported cases and literature and case report contribution. *J Clin Oncol*. 2011;29 Suppl 7:406.
4. Gunaldi M, Kara IO, Afsar CU, Duman BB. Sorafenib in the treatment of metastatic paraganglioma: a case report. *J Clin Oncol*. 2012;30 Suppl:e13523.
5. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. *Oncologist*. 2007;12:426–437.
6. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol*. 2006;24:4293–4300.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378–390.
8. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009;10:25–34.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228–247.

10. Dahia PL, Hao K, Rogus J, et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. *Cancer Res.* 2005;65: 9651–9658.
11. López-Jiménez E, Gómez-López G, Leandro-García LJ, et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. *Mol Endocrinol.* 2010;24:2382–2391.
12. Delman KA, Shapiro SE, Jonasch EW, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. *World J Surg.* 2006;30:665–669.
13. Boedeker CC, Erlic Z, Richard S, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. *J Clin Endocrinol Metab.* 2009;94:1938–1944.
14. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nat Genet.* 2011;43:663–667.
15. Buffet A, Venisse A, Nau V, et al. A decade (2001–2010) of genetic testing for pheochromocytoma and paraganglioma. *Horm Metab Res.* 2012;44:359–366.
16. Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. *Cancer Genet.* 2012;205:1–11.
17. Nolting S, Grossman AB. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. *Endocr Pathol.* 2012;23:21–33.
18. Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. *Endocr Pathol.* 2012;23:4–14.
19. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nat Rev Drug Discov.* 2006;5:835–844.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress